Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patients’ clinical characteristics

From: Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region

Sample   85  
Age   6-88 Median: 60
Gender Female 36  
  Male 49  
Removal Biopsy 1  
  Partial 29  
  Subtotal 28  
  Total 20  
  Unknown 8  
Post operative therapy VAC-feron 57  
  Temozolomide 14  
  Other ACNU regimen 4  
  Radiation alone 7  
  Other 3  
Overall survival (months) 3-96 Median: 12
Progression free survival (months) 1-96 Median: 6